AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28598894 — intervention group
Group type: EXPERIMENTAL
Intervention: 15° left tilt of the surgical table (tilt group)
Number of subjects: 100
Study 28598894 — intervention group
Group type: COMPARATOR
Intervention: Supine horizontal position (supine group)
Number of subjects: 100
Study 25655678 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 559
Study 25655678 — intervention group
Group type: COMPARATOR
Intervention: No diabetes
Number of subjects: 559
Study 25655678 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (in males)
Number of subjects: 559
Study 25655678 — intervention group
Group type: COMPARATOR
Intervention: Other metabolic factors and MetS
Number of subjects: 559
Study 23942586 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 7018
Study 23942586 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MedDiet)
Number of subjects: 7018
Study 21574208 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Intervention (MI)
Number of subjects: 467
Study 21574208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 467
Study 21574208 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (BUP)
Number of subjects: 467
Study 21574208 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacements (NRT)
Number of subjects: 467
Study 19185173 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimized cardiopulmonary bypass circuit
Number of subjects: 199
Study 19185173 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiopulmonary bypass circuit
Number of subjects: 199
Study 16430312 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran 48mg with food
Number of subjects: 24
Study 16430312 — intervention group
Group type: COMPARATOR
Intervention: Ximelagatran 48mg without food
Number of subjects: 24
Study 16430312 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated dosing of ximelagatran 48mg every 12 hours for 5 days
Number of subjects: 24
Study 16430312 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ximelagatran 48mg on day 6
Number of subjects: 24
Study 16430312 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated dosing of ximelagatran
Number of subjects: 24
Study 14667010 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer (Material A)
Number of subjects: 100
Study 14667010 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional glass-ionomer cement (Material B)
Number of subjects: 100
Study 14667010 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fissure sealant, received oral health education)
Number of subjects: 100
Study 10945014 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine plus AC (adriamycin + cyclophosphamide)
Number of subjects: 0
Study 10945014 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (monotherapy)
Number of subjects: 0
Study 10945014 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine plus 5-fluorouracil
Number of subjects: 0
Study 8857472 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptions under no time constraints
Number of subjects: 0
Study 8857472 — intervention group
Group type: COMPARATOR
Intervention: Descriptions under time pressure
Number of subjects: 0
Study 1582503 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment
Number of subjects: 224
Study 1582503 — intervention group
Group type: EXPERIMENTAL
Intervention: AR category (median value used as cut-off)
Number of subjects: 224
Study 1582503 — intervention group
Group type: EXPERIMENTAL
Intervention: AR content (greater than or equal to 10 pmol/g)
Number of subjects: 224
Study 1582503 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved AR assay
Number of subjects: 224
Study 6394217 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentin
Number of subjects: 64
Study 6394217 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 64
Study 30937964 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic mothers
Number of subjects: 163
Study 30937964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood samples
Number of subjects: 163
Study 30937964 — intervention group
Group type: COMPARATOR
Intervention: Male newborns
Number of subjects: 163
Study 30937964 — intervention group
Group type: COMPARATOR
Intervention: Maternal factors (age, pregnancy variables, allergens exposure, smoking, maternal IgE)
Number of subjects: 163
Study 30271133 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for ADRD using the Memory Impairment Screen
Number of subjects: 1723
Study 30271133 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, sex, and education of patients
Number of subjects: 1723
Study 27872111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound tailored treatment (disclosure of the ultrasound diagnosis)
Number of subjects: 129
Study 27872111 — intervention group
Group type: COMPARATOR
Intervention: Usual care (non-disclosure of the ultrasound diagnosis)
Number of subjects: 129
Study 23212894 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-based group program for mental health improvement
Number of subjects: 337
Study 22221670 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvisational music therapy (one session per week)
Number of subjects: 235
Study 22221670 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvisational music therapy (three sessions per week)
Number of subjects: 235
Study 22221670 — intervention group
Group type: COMPARATOR
Intervention: Parent counselling (three sessions at 0, 2, and 5 months)
Number of subjects: 235
Study 19781847 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 5 mg/d at bedtime
Number of subjects: 46
Study 19781847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 17959922 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanford V regimen
Number of subjects: 25
Study 17959922 — intervention group
Group type: COMPARATOR
Intervention: ABVD regimen
Number of subjects: 25
Study 15868015 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention for clinic staff (18-hour experiential, participatory in-service training programme)
Number of subjects: 1200
Study 15868015 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual DOTS strategy)
Number of subjects: 1200
Study 12501132 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (200 microg/day)
Number of subjects: 186
Study 12501132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 11682428 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway
Number of subjects: 0
Study 11682428 — intervention group
Group type: COMPARATOR
Intervention: Classic laryngeal mask airway
Number of subjects: 0
Study 9141524 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cetrorelix for 5 days followed by 2 mg/day
Number of subjects: 16
Study 9141524 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cetrorelix for 5 days followed by 2 x 1 mg/day
Number of subjects: 16
Study 9141524 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cetrorelix for 5 days followed by 1 mg/day
Number of subjects: 16
Study 9141524 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections for 3 weeks
Number of subjects: 16
Study 8246770 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g galactose
Number of subjects: 8
Study 8246770 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g galactose + 25 g glucose
Number of subjects: 8
Study 8246770 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g lactose
Number of subjects: 8
Study 8246770 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g glucose (reference)
Number of subjects: 8
Study 8246770 — intervention group
Group type: COMPARATOR
Intervention: Water only (control meal)
Number of subjects: 8
Study 3658567 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release methylphenidate (Ritalin [SR‐20])
Number of subjects: 22
Study 3658567 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard methylphenidate (Ritalin, 10 mg, administered twice daily)
Number of subjects: 22
Study 29914159 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapezoidal flap (Group I)
Number of subjects: 15
Study 29914159 — intervention group
Group type: COMPARATOR
Intervention: Modified triangular flap (Group II)
Number of subjects: 15
Study 27294433 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD with PRF
Number of subjects: 96
Study 27294433 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD with PRF + 1.2% ATV
Number of subjects: 96
Study 27294433 — intervention group
Group type: COMPARATOR
Intervention: OFD alone
Number of subjects: 96
Study 25169073 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-scheduled screening and treatment (CSST) using community health workers (CHW)
Number of subjects: 0
Study 23384442 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Intervention with typical community service (MI)
Number of subjects: 992
Study 23384442 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Intervention with exposure to a hospital trauma center (MI-H)
Number of subjects: 992
Study 23384442 — intervention group
Group type: COMPARATOR
Intervention: Enhanced prototypic community service (CS)
Number of subjects: 992
Study 23384442 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MI groups (MI and MI-H)
Number of subjects: 992
Study 20606123 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide signal peptide (BNPsp)
Number of subjects: 25
Study 20606123 — intervention group
Group type: EXPERIMENTAL
Intervention: BNPsp
Number of subjects: 25
Study 18345471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 0
Study 18345471 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 0
Study 18345471 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term Psychodynamic Psychotherapy (STPP)
Number of subjects: 0
Study 18345471 — intervention group
Group type: EXPERIMENTAL
Intervention: Client Centred Psychotherapy (CCPT)
Number of subjects: 0
Study 18345471 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of specific psychotherapies with antidepressive medication
Number of subjects: 0
Study 16888465 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adapted mouthguard (SA)
Number of subjects: 19
Study 16888465 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made mouthguard (CM)
Number of subjects: 19
Study 16888465 — intervention group
Group type: COMPARATOR
Intervention: Normal condition
Number of subjects: 19
Study 14524397 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic methods of pain relief (labor support, intradermal water blocks, warm water baths)
Number of subjects: 0
Study 14524397 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased availability of nonpharmacologic methods
Number of subjects: 0
Study 10947304 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol plus any NSAID therapy
Number of subjects: 8843
Study 10947304 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus any NSAID therapy
Number of subjects: 8843
Study 8869390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 37
Study 8869390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 1727091 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 568
Study 29889917 — intervention group
Group type: EXPERIMENTAL
Intervention: Presaturated cord
Number of subjects: 50
Study 29889917 — intervention group
Group type: COMPARATOR
Intervention: Diode laser
Number of subjects: 50
Study 29889917 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG laser
Number of subjects: 50
Study 29889917 — intervention group
Group type: COMPARATOR
Intervention: Er:YAG laser
Number of subjects: 50
Study 26562107 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting program (Healthy Families Massachusetts)
Number of subjects: 704
Study 25031330 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal urinary iodine concentration (UIC) < 1.0 mg/L
Number of subjects: 1617
Study 22688337 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (0.1 and 0.2 units/kg)
Number of subjects: 18
Study 22688337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19926367 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (approximately 2 MJ)
Number of subjects: 6
Study 19926367 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (net deficit of approximately 2 MJ)
Number of subjects: 6
Study 19926367 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction-plus-exercise (total energy deficit of approximately 2 MJ)
Number of subjects: 6
Study 19926367 — intervention group
Group type: COMPARATOR
Intervention: Control (rest)
Number of subjects: 6
Study 19926367 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 6
Study 18840867 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face training
Number of subjects: 607
Study 18840867 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-taught package
Number of subjects: 607
Study 18840867 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 607
Study 17068980 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions (including unmodified extinction, extinction with parental presence, preventive parent education)
Number of subjects: 0
Study 17068980 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated extinction, bedtime fading/positive routines, scheduled awakenings
Number of subjects: 0
Study 17068980 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatments
Number of subjects: 0
Study 17068980 — intervention group
Group type: COMPARATOR
Intervention: Standardized bedtime routines and positive reinforcement
Number of subjects: 0
Study 17068980 — intervention group
Group type: COMPARATOR
Intervention: Combination of behavioral therapies
Number of subjects: 0
Study 12920525 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) detection
Number of subjects: 60
Study 12920525 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile organic compound (VOC) localization
Number of subjects: 60
Study 10678261 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg by mouth once per day
Number of subjects: 69
Study 10678261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 9256128 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (740 or 910 mg/m2) followed by cisplatin (120 mg/m2) and vinblastine (5 mg/m2)
Number of subjects: 26
Study 9256128 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (340 mg/m2 4 days a week for 5 weeks, or 200 mg/m2 5 days a week for 6 weeks) before radiation therapy
Number of subjects: 26
Study 9256128 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 26
Study 9256128 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine
Number of subjects: 26
Study 8150921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic single sperm injection (ICSI)
Number of subjects: 23
Study 3539714 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% branched chain amino acids
Number of subjects: 37
Study 3539714 — intervention group
Group type: EXPERIMENTAL
Intervention: 53% branched chain amino acids
Number of subjects: 37
Study 3539714 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% branched chain amino acids
Number of subjects: 37
Study 3539714 — intervention group
Group type: COMPARATOR
Intervention: 0% branched chain amino acids
Number of subjects: 37
Study 3539714 — intervention group
Group type: COMPARATOR
Intervention: 16% branched chain amino acids
Number of subjects: 37
Study 28929356 — intervention group
Group type: EXPERIMENTAL
Intervention: High AAC score in elderly patients (Group A)
Number of subjects: 0
Study 28929356 — intervention group
Group type: COMPARATOR
Intervention: BMI ≥ 25 in patients with CR-POPF (Group C)
Number of subjects: 0
Study 28929356 — intervention group
Group type: COMPARATOR
Intervention: Male gender in patients with CR-POPF (Group C)
Number of subjects: 0
Study 28929356 — intervention group
Group type: COMPARATOR
Intervention: Soft pancreatic parenchyma in patients with CR-POPF (Group C)
Number of subjects: 0
Study 28929356 — intervention group
Group type: COMPARATOR
Intervention: Absence of MPD dilatation in patients with CR-POPF (Group C)
Number of subjects: 0
Study 28929356 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥ 25 in patients with CR-POPF (Group E)
Number of subjects: 0
Study 26861782 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 0
Study 26861782 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 26861782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24813581 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm blood pressure measurement
Number of subjects: 44
Study 24813581 — intervention group
Group type: COMPARATOR
Intervention: Upper arm blood pressure measurement
Number of subjects: 44
Study 24813581 — intervention group
Group type: COMPARATOR
Intervention: Upper arm/forearm systolic measures
Number of subjects: 44
Study 22678515 — intervention group
Group type: EXPERIMENTAL
Intervention: Coopdech videolaryngoscope (VLP-100)
Number of subjects: 50
Study 22678515 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Scope (AWS)
Number of subjects: 50
Study 22678515 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 50
Study 22678515 — intervention group
Group type: COMPARATOR
Intervention: All devices
Number of subjects: 50
Study 19818442 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Monounsaturated Fatty Acids (HMUFA) diet
Number of subjects: 0
Study 19818442 — intervention group
Group type: COMPARATOR
Intervention: High-Saturated Fatty Acids (HSFA) diet
Number of subjects: 0
Study 19818442 — intervention group
Group type: COMPARATOR
Intervention: Low-Fat High-Complex Carbohydrate (LFHCC) diet (placebo)
Number of subjects: 0
Study 19818442 — intervention group
Group type: COMPARATOR
Intervention: Low-Fat High-Complex Carbohydrate (LFHCC) diet (n-3 PUFA)
Number of subjects: 0
Study 18359651 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% pirenzepine ophthalmic gel
Number of subjects: 174
Study 18359651 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 174
Study 15834348 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal sterile barrier precautions (mask, cap, sterile gloves, gown, large drape)
Number of subjects: 82
Study 15834348 — intervention group
Group type: COMPARATOR
Intervention: Control precautions (mask, cap, sterile gloves, small drape)
Number of subjects: 82
Study 15834348 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent polyurethane film dressing
Number of subjects: 82
Study 15834348 — intervention group
Group type: COMPARATOR
Intervention: Gauze dressing
Number of subjects: 82
Study 15834348 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC related sepsis
Number of subjects: 82
Study 12464834 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation training
Number of subjects: 56
Study 12464834 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery training
Number of subjects: 56
Study 12464834 — intervention group
Group type: EXPERIMENTAL
Intervention: Both progressive muscle relaxation and guided imagery training
Number of subjects: 56
Study 12464834 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 10512401 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with hemophilia (group 2)
Number of subjects: 39
Study 10512401 — intervention group
Group type: COMPARATOR
Intervention: Children with maternal-fetal transmission (group 3)
Number of subjects: 39
Study 8528170 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Progenitor Cell Collection (PBPCC)
Number of subjects: 65
Study 8528170 — intervention group
Group type: COMPARATOR
Intervention: Bone Marrow Harvest (BMH)
Number of subjects: 65
Study 8528170 — intervention group
Group type: EXPERIMENTAL
Intervention: PBPCC with femoral catheter
Number of subjects: 65
Study 8528170 — intervention group
Group type: EXPERIMENTAL
Intervention: PBPCC
Number of subjects: 65
Study 1723460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20‐40 mg daily)
Number of subjects: 34
Study 1723460 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20‐40 mg daily)
Number of subjects: 34
Study 1723460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 34
Study 1723460 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 34
Study 7470225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg IV)
Number of subjects: 50
Study 7470225 — intervention group
Group type: COMPARATOR
Intervention: Control (no cimetidine)
Number of subjects: 50
Study 30725505 — intervention group
Group type: EXPERIMENTAL
Intervention: AccessMedicine
Number of subjects: 42
Study 30725505 — intervention group
Group type: EXPERIMENTAL
Intervention: AccessMedicine (high GPA subgroup)
Number of subjects: 42
Study 30725505 — intervention group
Group type: EXPERIMENTAL
Intervention: AccessMedicine (low GPA subgroup)
Number of subjects: 42
Study 30725505 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 25085115 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU staffing intervention
Number of subjects: 0
Study 25085115 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25376730 — intervention group
Group type: EXPERIMENTAL
Intervention: 500ml of water
Number of subjects: 13
Study 25376730 — intervention group
Group type: COMPARATOR
Intervention: 50ml of water (control)
Number of subjects: 13
Study 24354263 — intervention group
Group type: EXPERIMENTAL
Intervention: travoprost-timolol fixed combination (PG group)
Number of subjects: 66
Study 24354263 — intervention group
Group type: COMPARATOR
Intervention: travoprost-timolol fixed combination (PG+BB group)
Number of subjects: 66
Study 24354263 — intervention group
Group type: COMPARATOR
Intervention: travoprost-timolol fixed combination (both groups)
Number of subjects: 66
Study 21075163 — intervention group
Group type: EXPERIMENTAL
Intervention: Test vaccine recipients
Number of subjects: 48